Endostatin, a natural peptide fragment from collagen, is one of the most potent inhibitors of blood vessel growth and has emerging roles as both a cancer biomarker and therapeutic agent.
20-kDa natural anti-angiogenicEndostatin is a fragment of type XVIII collagen and ranks among the most potent known inhibitors of new blood vessel formation.
What the researchers found
Endostatin — a 20-kDa peptide fragment naturally derived from type XVIII collagen — is one of the most potent known inhibitors of angiogenesis (new blood vessel formation). This review synthesizes a decade of research showing that endostatin works through multiple mechanisms: it binds to several different receptors, inhibits both blood vessel and lymphatic vessel growth, and can suppress cancer metastasis. The paper highlights endostatin's emerging role as both a disease biomarker (abnormal levels correlate with various diseases) and a potential therapeutic agent, particularly in short peptide form.
Why it matters
Tumors need blood vessels to grow and spread. Endostatin was initially hyped as a potential cancer cure, and while reality proved more complex, this review shows it remains a highly relevant molecule. Its dual potential as a biomarker for disease states and as a therapeutic peptide keeps it firmly in the research pipeline. Understanding endostatin's multiple mechanisms could lead to more effective anti-cancer combination therapies.
The numbers in context
20-kDa peptide fragment · Derived from type XVIII collagen · Multiple receptor targets · Inhibits both angiogenesis and lymphangiogenesis
How the study worked
This is a comprehensive review paper synthesizing published research on endostatin's biology, mechanisms of action, and clinical applications. The authors reviewed studies spanning endostatin's endogenous production, receptor binding, anti-angiogenic and anti-lymphangiogenic effects, cancer metastasis inhibition, and emerging clinical uses.
Who was studied
Review of published literature (no direct study population)
What this study cannot tell us
As a review paper, this study doesn't present new experimental data. The clinical translation of endostatin has been slower than initially hoped, and the complexity of its multiple mechanisms makes it challenging to predict therapeutic outcomes. Some of the clinical applications discussed were still emerging at the time of publication.
How to read the evidence
This is a moderate-strength review paper that comprehensively synthesizes existing research but doesn't present new experimental data. The quality of evidence it summarizes ranges from preclinical animal studies to emerging clinical applications.
When this study was published
Published in 2015. Endostatin research has continued to advance, particularly regarding short peptide derivatives and biomarker applications. Check for more recent clinical trial data.
The bigger picture
Anti-angiogenic therapy is a cornerstone of modern cancer treatment, with drugs like bevacizumab (Avastin) used in multiple cancer types. Endostatin represents a different approach — a naturally occurring peptide rather than an engineered antibody. The trend toward developing shorter peptide versions of endostatin aligns with the broader pharmaceutical push to create smaller, more practical peptide therapeutics that are easier to manufacture and administer.
Questions still open
- Can short peptide versions of endostatin be developed into practical, affordable cancer treatments?
- How reliable is endostatin as a biomarker for monitoring cancer progression or treatment response?
- What is the optimal way to combine endostatin with other cancer therapies for maximum benefit?
Common questions
What is endostatin and where does it come from in the body?
Is endostatin used as a cancer treatment today?
Read the original research
Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.
Biochimica et biophysica acta, 1850(12), 2422-38
Citation
Walia, Amit; Yang, Jessica F; Huang, Yu-Hui; Rosenblatt, Mark I; Chang, Jin-Hong; Azar, Dimitri T. (2015). Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.. Biochimica et biophysica acta, 1850(12), 2422-38. https://doi.org/10.1016/j.bbagen.2015.09.007